P32/98 (hemi<wbr>fumarate)

P32/98 (hemifumarate)

CAT N°: 16887
Price:

From 74.00 62.90

The glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are responsible for a majority of nutrient-stimulated insulin secretion. After being released into the circulation, GIP and GLP-1 are inactivated by the circulating enzyme dipeptidyl peptidase IV (DPP IV). DPP IV inhibitors have emerged as a new class of experimental antidiabetic agents. P32/98 is a competitive transition-state substrate analog inhibitor of DPP IV (Ki = 126 nM).{24373} At 20 mg/kg/day, it has been used to improve glucose tolerance, insulin sensitivity, and ?-cell glucose responsiveness in diabetic rat models.{27894}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (2S,3S)-2-amino-3-methyl-1-(3-thiazolidinyl)-1-pentanone, 2E-butenedioate (2:1)
  • Correlated keywords
    • 136259-20-6 335149-?22-?9 DPP-4 dipeptidyl peptidase DPP IV inhibitor type 2 diabetes insulin resistance biochemical two glucose-dependent insulinotropic polypeptide GIP glucagon-like peptide 1 GLP-1 GLP1 DPPIV DPP4 nutrient-stimulated secretion circulating enzyme experimental antidiabetic agent P3298 P32-98 competitive transition-state substrate analog tolerance sensitivity ?-cell responsiveness diabetic rat model inhibit
  • Product Overview:
    The glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are responsible for a majority of nutrient-stimulated insulin secretion. After being released into the circulation, GIP and GLP-1 are inactivated by the circulating enzyme dipeptidyl peptidase IV (DPP IV). DPP IV inhibitors have emerged as a new class of experimental antidiabetic agents. P32/98 is a competitive transition-state substrate analog inhibitor of DPP IV (Ki = 126 nM).{24373} At 20 mg/kg/day, it has been used to improve glucose tolerance, insulin sensitivity, and ?-cell glucose responsiveness in diabetic rat models.{27894}

We also advise you